Clinical characteristics | TDF group no (%) | AZT group no (%) | P value |
---|---|---|---|
Baseline CD4+ count | |||
<200 | 92 (65.7) | 74 (53.9) | 0.029* |
≥200 | 48 (34.3) | 66 (47.1) | |
Mean (SD) | 164.64 (83.36) | 175.21 (89.14) | 0.307** |
Baseline WHO clinical stage | |||
I | 32 (22.9) | 36 (25.7) | |
II | 46 (32.9) | 47 (33.6) | 0.928 |
III | 47 (33.6) | 43 (30.7) | |
IV | 15 (10.6) | 14 (10) | |
Baseline functional status | |||
W | 110 (78.6) | 79 (56.4) | |
A | 24 (17.1) | 56 (40.0) | 0.000* |
B | 6 (4.3) | 5 (3.6) | |
TB Treatment | |||
No | 120 (84.7) | 113 (87.9) | 0.773 |
Yes | 20 (15.3) | 17 (12.1) | |
Prophylaxis | |||
CPT+ INH | 37 (26.4) | 30 (21.5) | |
CPT alone | 86 (61.4) | 99 (70.7) | 0.231 |
Neither | 17 (12.2) | 11 (7.8) |